Clinical Trial Update: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED) [Phase 2]

View source ↗

Summary

Phase IIb study evaluating four dose regimens of BAY1021189 in heart failure with reduced ejection fraction (SOCRATES-REDUCED) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• BAY1021189 (BAY1021189)

Snippet

Sponsor: Bayer | Conditions: Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2021-03-25